Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

Exclusion Criteria

• •Concomitant use of systemic immunosuppressant drugs.
• •Abnormal LFTs.
• •Any life-threatening disease expected to result in death within 12 months.
• •A history of GI perforation, inflammatory bowel disease (except fully excised. ulcerative colitis), or peptic ulcer disease.
• •Clinically significant active infection or history of opportunistic or invasive fungal infection.